Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches

Experimental Hematology & Oncology

Review

Alex F. Herrera¹  Walter Hanel²  Narendranath Epperla³ 

[1] Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, 1500 E Duarte Rd, 91010, Duarte, CA, USA;Division of Hematology, Department of Medicine, The James Cancer Hospital and Solove Research Institute, The Ohio State University, 460 W 10th Ave, 43210, Columbus, OH, USA;Division of Hematology, Department of Medicine, The James Cancer Hospital and Solove Research Institute, The Ohio State University, 460 W 10th Ave, 43210, Columbus, OH, USA;The Ohio State University Comprehensive Cancer Center, 1110E Lincoln Tower, 1800 Cannon Drive, 43210, Columbus, OH, USA;

关键词: Hodgkin lymphoma;    cHL;    Brentuximab vedotin;    Nivolumab;    Pembrolizumab;   

DOI  :  10.1186/s40164-022-00360-4

 received in 2022-10-02, accepted in 2022-12-16,  发布年份 2022

来源: Springer

【 摘 要 】

The treatment landscape of classical Hodgkin lymphoma (cHL) has undergone significant changes over the past 20 years. Gradual improvements have been made in the management of cHL patients, particularly in prolonging the survival rate for those in the relapsed setting. Most of these improvements came with the addition of brentuximab vedotin and PD1 blockade (nivolumab and pembrolizumab) into the current cHL treatment algorithms. On the other hand, the treatment approach to cHL has become more complex than ever before, with multiple ways to add and sequence therapies to achieve long-term remission. In this review, we will discuss the most up-to-date evidence on the management of cHL patients with the inclusion of ongoing clinical trials in cHL. We will provide a general overview of the current therapeutic landscape of cHL in light of these most recent data. We conclude with our perspective on how the approach to cHL treatment may evolve in the future.

【 授权许可】

CC BY   
© The Author(s) 2022